Takeda Pharmaceutical Company Limited
【Takeda Pharmaceutical】 Jury Verdict in US Antitrust Lawsuit and Financial Adjustment ｜ May 2026
Takeda Pharmaceutical is considering revising financial results for the fiscal year ending March 2026 due to a US antitrust lawsuit. A jury verdict has recognized damages of 884,943,990 USD, pending court ruling. Reserves will be booked, and financial statements will be revised.
Key Figures
- Damages awarded: 884,943,990 USD (recognized by jury verdict)
- Threefold damages: 474,897,965 USD (wholesaler class) + 346,837,646 USD (retail pharmacy class)
- Financial adjustment planning: to be revised after reserve is finalized for FY2026
AI要約
Overview of Financial Results and Lawsuit
Takeda Pharmaceutical's jury verdict in the US antitrust lawsuit has recognized damages of 884,943,990 USD, with the court's ruling pending. The damages are subject to triple damages, and reserves are planned to be booked with an adjustment to the financial results for the fiscal year ending March 2026. The lawsuit relates to a 2014 settlement agreement involving generic drug launches and patent infringement claims. The company intends to contest the lawsuit through legal channels.
Future Actions and Outlook
The company is currently reviewing the reserve amount, which will be reflected in the financial statements after determination. The timing and amount of the court ruling could impact the financial position, but it is expected to have minimal effect on the FY2025 results. The company will continue to handle legal matters and disclose information as appropriate.
Takeda Pharmaceutical Company Limited
Company overview · Stock price · Financial data · All IR
